The USFDA has approved durvalumab in combination with platinum-based chemotherapy as a neoadjuvant treatment to treat adults with resectable non-small cell lung cancer (NSCLC). This combination therapy is indicated for NSCLC patients with no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements. In addition, this therapy should be followed by an adjuvant treatment with single-agent durvalumab after surgery.
Clinical evidence In a clinical trial conducted on 802 NSCLC patients, durvalumab combination therapy achieved a remarkable 17.2% pathological complete response rate compared to 4.3% in the placebo with chemotherapy group. Administration IV infusion over 60 minutes Neoadjuvant therapy: Every three weeks for up to four cycles before surgery Adjuvant therapy: Every four weeks for up to 12 cycles after surgery Warnings Immune-mediated adverse…
